scholarly journals Particle therapy using carbon ions or protons as a definitive therapy for patients with primary sacral chordoma

2014 ◽  
Vol 87 (1033) ◽  
pp. 20130512 ◽  
Author(s):  
M Mima ◽  
Y Demizu ◽  
D Jin ◽  
N Hashimoto ◽  
M Takagi ◽  
...  
Keyword(s):  
Particle Therapy ◽  
Carbon Ions ◽  
Sacral Chordoma ◽  
Definitive Therapy

scholarly journals Carbon Ion Radiobiology

Cancers ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 3022 ◽  
Author(s):  
Walter Tinganelli ◽  
Marco Durante
Keyword(s):  
Normal Tissue ◽  
Biological Response ◽  
Metastatic Potential ◽  
Clinical Results ◽  
Heavy Ion ◽  
Particle Therapy ◽  
X Rays ◽  
Carbon Ions ◽  
Treatment Protocols ◽  
Target Region

Radiotherapy using accelerated charged particles is rapidly growing worldwide. About 85% of the cancer patients receiving particle therapy are irradiated with protons, which have physical advantages compared to X-rays but a similar biological response. In addition to the ballistic advantages, heavy ions present specific radiobiological features that can make them attractive for treating radioresistant, hypoxic tumors. An ideal heavy ion should have lower toxicity in the entrance channel (normal tissue) and be exquisitely effective in the target region (tumor). Carbon ions have been chosen because they represent the best combination in this direction. Normal tissue toxicities and second cancer risk are similar to those observed in conventional radiotherapy. In the target region, they have increased relative biological effectiveness and a reduced oxygen enhancement ratio compared to X-rays. Some radiobiological properties of densely ionizing carbon ions are so distinct from X-rays and protons that they can be considered as a different “drug” in oncology, and may elicit favorable responses such as an increased immune response and reduced angiogenesis and metastatic potential. The radiobiological properties of carbon ions should guide patient selection and treatment protocols to achieve optimal clinical results.

Space-Making Particle Therapy with Surgical Spacer Placement in Patients with Sacral Chordoma

2020 ◽  
Vol 230 (2) ◽  
pp. 207-215
Author(s):  
Daisuke Tsugawa ◽  
Shohei Komatsu ◽  
Yusuke Demizu ◽  
Nor Shazrina Sulaiman ◽  
Masaki Suga ◽  
...  
Keyword(s):  
Particle Therapy ◽  
Sacral Chordoma

scholarly journals Brain MR findings in patients treated with particle therapy for skull base tumors

2019 ◽  
Vol 10 (1) ◽  
Author(s):  
Gisela Viselner ◽  
Lisa Farina ◽  
Federica Lucev ◽  
Elena Turpini ◽  
Luca Lungarotti ◽  
...  
Keyword(s):  
Skull Base ◽  
Radiation Necrosis ◽  
Correct Diagnosis ◽  
Severe Form ◽  
Particle Therapy ◽  
Focal Lesion ◽  
Carbon Ions ◽  
Skull Base Tumors ◽  
Delayed Effects ◽  
Normal Tissues

Abstract Nowadays, hadrontherapy is increasingly used for the treatment of various tumors, in particular of those resistant to conventional radiotherapy. Proton and carbon ions are characterized by physical and biological features that allow a high radiation dose to tumors, minimizing irradiation to adjacent normal tissues. For this reason, radioresistant tumors and tumors located near highly radiosensitive critical organs, such as skull base tumors, represent the best target for this kind of therapy. However, also hadrontherapy can be associated with radiation adverse effects, generally referred as acute, early-delayed and late-delayed. Among late-delayed effects, the most severe form of injury is radiation necrosis. There are various underlying mechanisms involved in the development of radiation necrosis, as well as different clinical presentations requiring specific treatments. In most cases, radiation necrosis presents as a single focal lesion, but it can be multifocal and involve a single or multiple lobes simulating brain metastasis, or it can also involve both cerebral hemispheres. In every case, radiation necrosis results always related to the extension of radiation delivery field. Multiple MRI techniques, including diffusion, perfusion imaging, and spectroscopy, are important tools for the radiologist to formulate the correct diagnosis. The aim of this paper is to illustrate the possible different radiologic patterns of radiation necrosis that can be observed in different MRI techniques in patients treated with hadrontherapy for tumors involving the skull base. The images of exemplary cases of radiation necrosis are also presented.

Particle Therapy Using Protons or Carbon Ions for Unresectable or Incompletely Resected Bone and Soft Tissue Sarcomas of the Pelvis

2017 ◽  
Vol 98 (2) ◽  
pp. 367-374 ◽  
Author(s):  
Yusuke Demizu ◽  
Dongcun Jin ◽  
Nor Shazrina Sulaiman ◽  
Fumiko Nagano ◽  
Kazuki Terashima ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Particle Therapy ◽  
Carbon Ions

CHARGED PARTICLE THERAPY STEPS INTO THE CLINICAL ENVIRONMENT

2007 ◽  
Vol 16 (04) ◽  
pp. 1205-1220 ◽  
Author(s):  
TH. HABERER
Keyword(s):  
Charged Particle ◽  
Charged Particles ◽  
Basic Research ◽  
Particle Therapy ◽  
Treatment Modalities ◽  
Carbon Ions ◽  
Clinical Environment ◽  
Heavy Charged Particles ◽  
Charged Particle Therapy ◽  
Beam Delivery

Beams of heavy charged particles like protons or carbon ions represent the ideal tool for the treatment of deep-seated, inoperable and radioresistant tumors. For more than 4 decades research with beams of charged particles has been performed. In total more than 40000 patients have been treated, mostly using protons being delivered by accelerators that were designed for basic research centers. In Berkeley, USA heavier particles like helium or neon ions were used to conduct clinical trials until 1992. Based on that somewhat limited technological standard and triggered by the promising results from Berkeley the first dedicated charged particle facilities were constructed. In order to maximally exploit the advantageous physical and radiobiological characteristics of these beams enormous effort was put into developing dynamic beam delivery techniques and tailoring the capabilities of the accelerators, the planning systems and the quality assurance procedures and equipment to the requirements resulting from these new treatment modalities. Active beam delivery systems integrated in rotating gantries, if necessary, will allow the production of superior dose distributions that precisely follow the medical prescription. The technological progress being made during the last 10 years defines the state of the art of the upcoming next-generation facilities for the clinical environment in Europe and Japan.

scholarly journals Proton Therapy for Intracranial Meningioma for the Treatment of Primary/Recurrent Disease Including Re-Irradiation

2020 ◽  
Vol 10 ◽  
Author(s):  
Damien C. Weber ◽  
Nicola Bizzocchi ◽  
Alessandra Bolsi ◽  
Michael D. Jenkinson
Keyword(s):  
Effective Means ◽  
Local Tumor Control ◽  
Particle Therapy ◽  
Benign Tumors ◽  
Tumor Control ◽  
Intracranial Meningioma ◽  
Normal Brain ◽  
Carbon Ions ◽  
Local Tumor ◽  
Who Grade

Meningeal tumors represent approximately 10–25% of primary brain tumors and occur usually in elderly female patients. Most meningiomas are benign (80–85%) and for symptomatic and/or large tumors, surgery, with or without radiation therapy (RT), has been long established as an effective means of local tumor control. RT can be delivered to inoperable lesions or to those with non-benign histology and for Simpson I–III and IV–V resection. RT can be delivered with photons or particles (protons or carbon ions) in stereotactic or non-stereotactic conditions. Particle therapy delivered for these tumors uses the physical properties of charged carbon ions or protons to spare normal brain tissue (i.e. Bragg peak), with or without or a dose-escalation paradigm for non-benign lesions. PT can substantially decrease the dose delivered to the non-target brain tissues, including but not limited to the hippocampi, optic apparatus or cochlea. Only a limited number of meningioma patients have been treated with PT in the adjuvant or recurrent setting, as well as for inoperable lesions with pencil beam scanning and with protons only. Approximately 500 patients with image-defined or WHO grade I meningioma have been treated with protons. The reported outcome, usually 5-year local tumor control, ranges from 85 to 99% (median, 96%). For WHO grade II or III patients, the outcome of only 97 patients has been published, reporting a median tumor local control rate of 52% (range, 38–71.1). Only 24 recurring patients treated previously with photon radiotherapy and re-treated with PT were reported. The clinical outcome of these challenging patients seems interesting, provided that they presented initially with benign tumors, are not in the elderly category and have been treated previously with conventional radiation dose of photons. Overall, the number of meningioma patients treated or-re-irradiated with this treatment modality is small and the clinical evidence level is somewhat low (i.e. 3b–5). In this review, we detail the results of upfront PT delivered to patients with meningioma in the adjuvant setting and for inoperable tumors. The outcome of meningioma patients treated with this radiation modality for recurrent tumors, with or without previous RT, will also be reviewed.

Sign in / Sign up

Export Citation Format

Share Document